Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful conscientiously but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my last several shares. My first CytoDyn article, “CytoDyn: What To Do When It is Too Good In order to Be True?”, set out the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such an extremely promotional picture in the Uptick Newswire employment interview that I came away with an inadequate opinion of the business.

Irony of irony, my bad opinion of the company has grown steadily, though the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s payment of $3.5 million transfers ownership of this technology and also connected intellectual property from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 huge number of) as well as the very first brand new drug application endorsement ($five million), as well as royalty payments of five percent of net sales upon commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to get a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and numerous therapies, it’s this single therapy as well as a “broad pipeline of indications” because it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially beneficial therapy of dozens of indications.

The opening banner of its on its site (below) shows an energetic organization with diverse interests albeit focused on leronlimab, multiple disease types, multiple publications in addition to multiple presentations.

Can it all be smoke cigarettes and mirrors? That’s a question I’ve been asking myself through the very start of the interest of mine in this organization. Judging with the multiples of thousands of various responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this question.

CytoDyn is a traditional battleground, or some may say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *